Last Update: Jul 16, 2026 Real-World Characteristics, Treatment Patterns, and Outcomes Among Adults With mCRPC Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan ClinicalTrials.gov Identifier: [NCT07677267](https://clinicaltrials.gov/ct2/show/NCT07677267) Novartis Reference Number:CAAA617A1US30 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description The aim of this study is to assess treatment patterns, characteristics, and clinical outcomes among adults with metastatic castration-resistant prostate cancer (mCRPC) who have previously received ≥1 androgen receptor pathway inhibitor (ARPI), ≥1 taxane, and 177Lu-PSMA-617 in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform. Condition Prostatic Neoplasms, Castration-Resistant Overall Status Recruiting Number of Participants1067 Start Date Jun 30, 2026 Completion Date Nov 30, 2026 Gender Male Age(s) 18 Years - 115 Years (Adult, Older Adult) ## Eligibility Criteria Inclusion criteria: \* Evidence of 177Lu-PSMA-617 use on or after 01 January 2021. \* Evidence of treatment with ≥1 ARPI, before 177Lu-PSMA-617. \* Evidence of treatment with ≥1 taxane, before or after 177Lu-PSMA-617. \* Diagnosis of mCRPC prior to or on the index date. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617. \* Age ≥18 years at index. Exclusion criteria: • None. United States #### Novartis Recruiting East Hanover,New Jersey,07936,United States ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: